Last reviewed · How we verify

Basal cell carcinoma of skin — Treatment Landscape & Competitive Intelligence

Basal cell carcinoma of skin (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Basal cell carcinoma of skin, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Erivedge vismodegib Roche Hedgehog Pathway Inhibitor [EPC] Smoothened 2012-01-01
Erismodegib Erismodegib Washington University School of Medicine Smoothened homolog, Sonic hedgehog protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Roche · 1 drug in Basal cell carcinoma of skin
  2. Washington University School of Medicine · 1 drug in Basal cell carcinoma of skin

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Basal cell carcinoma of skin:

Cite this brief

Drug Landscape (2026). Basal cell carcinoma of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/basal-cell-carcinoma-of-skin. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing